News & Updates

Show Multimedia Only

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023 by

Patients with Alagille syndrome (AS) may benefit from treatment with odevixibat, with the phase III ASSERT study showing that its use results in rapid, sustained, and highly significant improvements in pruritus, sleep quality, as well as decreases in bile acids (BAs). Odevixibat is also well tolerated.

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

16 Jun 2023

NAFLD a risk factor for young-onset hypertension

09 Jun 2023

Young people with nonalcoholic fatty liver disease (NAFLD) are at increased risk of hypertension, especially women and those with more severe hepatic steatosis, as shown in a study.

NAFLD a risk factor for young-onset hypertension

09 Jun 2023

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023 by

In individuals with hepatorenal syndrome (HRS) compounded by alcoholic hepatitis (AH), treatment with the synthetic, long-acting vasopressin analogue terlipressin led to the achievement of verified HRS reversal, a subgroup analysis of the phase III CONFIRM trial has shown.

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023

New data fortify obeticholic acid role in NASH treatment

29 May 2023 by

In the new analysis of the REGENERATE trial, the FXR* agonist obeticholic acid (OCA) was generally well tolerated and demonstrated a favourable safety profile in patients with nonalcoholic steatohepatitis (NASH).

New data fortify obeticholic acid role in NASH treatment

29 May 2023

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

25 May 2023 by

The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

25 May 2023

SGLT2 inhibitors reduce HCC risk in T2DM patients with CHB

18 May 2023 by

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a reduced risk of incident hepatocellular carcinoma (HCC) in patients with coexisting type 2 diabetes mellitus (T2DM) and chronic hepatitis B (CHB), a territory-wide cohort study in Hong Kong has shown.

SGLT2 inhibitors reduce HCC risk in T2DM patients with CHB

18 May 2023

SBRT effective, well tolerated for unresectable liver metastases

15 May 2023 by

A retrospective study in Hong Kong has shown that stereotactic body radiotherapy (SBRT) is an effective and well-tolerated treatment for patients with unresectable liver metastases.

SBRT effective, well tolerated for unresectable liver metastases

15 May 2023

Type 2 hepatitis no different from type 1 in terms of outcome

02 May 2023

Liver outcomes do not differ between types 1 and 2 autoimmune hepatitis presenting in childhood, reports a recent study.

Type 2 hepatitis no different from type 1 in terms of outcome

02 May 2023

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

26 Apr 2023

Adherence to a diet rich in protein and unsaturated fatty acids (UFAs) helps improve liver fat and lipid metabolism in people at risk of unhealthy ageing, a recent study has shown.

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

26 Apr 2023

Adverse events occur in two-thirds of NASH patients on placebo

24 Apr 2023

Nearly two in three participants in the placebo arm of nonalcoholic steatohepatitis (NASH) randomized clinical trials (RCTs) experience an adverse event (AE), while one in 10 have a serious AE, according to a pooled analysis of studies with NASH placebo.

Adverse events occur in two-thirds of NASH patients on placebo

24 Apr 2023

News & Updates

Showing Hepatology articles

Showing

Specialty:

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

Odevixibat reduces bile acids, improves sleep, pruritus in Alagille syndrome

NAFLD a risk factor for young-onset hypertension

NAFLD a risk factor for young-onset hypertension

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

New data fortify obeticholic acid role in NASH treatment

New data fortify obeticholic acid role in NASH treatment

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

SGLT2 inhibitors reduce HCC risk in T2DM patients with CHB

SGLT2 inhibitors reduce HCC risk in T2DM patients with CHB

SBRT effective, well tolerated for unresectable liver metastases

SBRT effective, well tolerated for unresectable liver metastases

Type 2 hepatitis no different from type 1 in terms of outcome

Type 2 hepatitis no different from type 1 in terms of outcome

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

Adverse events occur in two-thirds of NASH patients on placebo

Adverse events occur in two-thirds of NASH patients on placebo